TFRC and neoplasm: After verifying that HPPS-mAb nanoparticles could deliver DiR-BOA cargo specifically into TfR+ tumor in vivo, HPPS-mAb was incorporated by other hydrophobic therapeutic payloads to test its potential suitability for the targeted delivery of clinical relevant cancer therapeutics.